Welcome to CDC Stacks | Reversal of Growth Arrest with the Combined Administration of Oxandrolone and Propranolol in Severely Burned Children - 43295 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Reversal of Growth Arrest with the Combined Administration of Oxandrolone and Propranolol in Severely Burned Children
  • Published Date:
    Sep 2016
  • Source:
    Ann Surg. 264(3):421-428.


Public Access Version Available on: September 01, 2017 information icon
Please check back on the date listed above.
Details:
  • Pubmed ID:
    27433905
  • Pubmed Central ID:
    PMC5167626
  • Description:
    Background

    The hypercatabolic response in severely burned pediatric patients is associated with increased production of catecholamines and corticosteroids, decreased formation of testosterone, and reduced strength alongside growth arrest for up to 2 years post injury. We have previously shown that, in the pediatric burned population, the administration of the testosterone analog oxandrolone improves lean body mass accretion and bone mineral content and that the administration of the β1, β2 adrenoreceptor antagonist propranolol decreases cardiac work and resting energy expenditure while increasing peripheral lean mass. Here, we determined whether the combined administration of oxandrolone and propranolol has added benefit.

    Methods

    In this prospective, randomized study of 612 burned children (52 ± 1% of total body surface area burned, ages 0.5–14 years [males]; ages 0.5–12 years [females]), we compared controls to the individual administration of these drugs, and the combined administration of oxandrolone and propranolol at the same doses, for 1 year post burn. Data were recorded at discharge, 6 months, and 1 and 2 years post injury.

    Results

    Combined use of oxandrolone and propranolol shortened the period of growth arrest by 84 days (p=0.0125 vs. control) and increased growth rate by 1.7 cm/y (p=0.0024 vs. control).

    Conclusion

    Combined administration of oxandrolone and propranolol attenuates burn-induced growth arrest in pediatric burn patients. This study is registered at clinicaltrials.gov: NCT00675714 and NCT00239668. Growth Arrest and Growth Rate By Treatment GroupTreatmentLength of Growth Arrest(Days)Growth Rate(cm/y)Control280 ± 195.9 ± 0.2Oxandrolone217 ± 175.8 ± 0.3Propranolol242 ± 136.3 ± 0.2Oxandrolone + Propranolol196 ± 15*7.6 ± 0.5*Data presented as mean ± standard error.*p<0.05 vs. control.

  • Document Type:
  • Collection(s):
  • Funding:
    R01 HD049471/HD/NICHD NIH HHS/United States
    R01 GM112936/GM/NIGMS NIH HHS/United States
    U48 DP000043/DP/NCCDPHP CDC HHS/United States
    R01 GM056687/GM/NIGMS NIH HHS/United States
    P50 GM060338/GM/NIGMS NIH HHS/United States
    T32 GM008256/GM/NIGMS NIH HHS/United States
    UL1 TR001439/TR/NCATS NIH HHS/United States
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like: